Jaypirca (pirtobrutinib) / Eli Lilly, Innovent Biologics, Nippon Shinyaku - LARVOL DELTA

The safety and efficacy of pirtobrutinib in adults with immune thrombocytopenia: A phase 1/2 dose-finding study in progress (ASH 2025) - P1/2 | "Exclusion criteria include treatment other than corticosteroids or TPO-RA for ITP within 2 weeks of visit 1, use of anticoagulants or antiplatelet therapy, history of any thrombotic or embolic event within 12 months before screening, hematologic malignancy, and significant cardiovascular disease. Results : This study is a Trial in Progress, and enrollment is ongoing."

Clinical • P1/2 data • Cardiovascular • Hematological Malignancies • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Incidence of cardiac events associated with next-generation bruton tyrosine kinase (BTK) inhibitors compared to control in hematologic malignancies: A meta-analysis of randomized trials (ASH 2025) - "Most existing data are derived from studies of ibrutinib, the first generation BTKi which has known off-target receptor binding that may contribute to cardiotoxicity...Acalabrutinib was evaluated in four trials (ECHO, ELEVATE-TN, ASCEND, AMPLIFY), zanubrutinib in two (SEQUOIA, ROSEWOOD), and pirtobrutinib in one (BRUIN CLL-321)... This analysis of seven RCTs found that next-generation BTKi were associated with an elevated risk of atrial arrhythmias, particularly atrial fibrillation or flutter; however, the incidence of more severe cardiac events such as ventricular arrhythmias and myocardial infarction remains low and not significantly different between groups. The increased incidence of atrial rhythm disturbances may have important clinical implications, especially for patients with underlying cardiovascular risk. As use of these agents expands, clinicians should remain vigilant regarding potential cardiac effects and consider baseline evaluation and ongoing monitoring."

Retrospective data • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Hematological Malignancies • Myocardial Infarction • Oncology • Ventricular Tachycardia

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States (ASH 2025) - "Treatment regimens were categorized into 7 mutually exclusive groups: bendamustine (B)-based chemotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without cytarabine), Bruton tyrosine kinase inhibitors (BTKi; covalent: zanubrutinib, acalabrutinib, ibrutinib, and non-covalent: pirtobrutinib), bortezomib (bort)-based, venetoclax (ven)-based, intensive chemotherapy (high-dose cytarabine, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, etc.), and other regimens (CAR-T or others). However, chemotherapy and/or immunotherapy were associated with the highest HCRU while BTKi were associated with the lowest HCRU. Notably, more than half of patients previously treated with BTKi and anti-CD20 therapies were subsequently treated with another covalent BTKi or a non-covalent BTKi, while approximately one-third received chemotherapy and/or immunotherapy, further emphasizing the need for novel..."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells. (ASH 2025) - "The ZAP combination exhibited more potent synergistic inhibition of BTK signaling and downstream survival pathways versus zanubrutinib or pirtobrutinib alone or IAP in MYD88 mutated lymphomas. ZAP was also active in MYD88 mutated lymphoma cells expressing mutated BTK Cys481. The results support the investigation of ZAP as a novel therapeutic approach to overcome resistance and improve outcomes in patients with MYD88 mutated B-cell malignancies."

Tumor cell • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia • GAPDH • MYD88 • PLCG2

Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis (ASH 2025) - "BTK inhibitors used in the studies included ibrutinib (67%, n = 775), acalabrutinib (31%, n = 363), and pirtobrutinib (2%, n = 25). Anti-CD 20 antibody was added in 188 patients, Obinutuzumab in 163 (87%), and Rituximab in 25 (13%) patients... The fixed-duration combination of BTK inhibitors and venetoclax shows very promising response rates compared to either of these agents as monotherapy. This necessitates the continuation of high-quality trials to consolidate these findings."

IO biomarker • Retrospective data • Review • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients (ASH 2025) - P3 | "A recent headto-head phase 3 trial (BRUIN CLL-314 presented at this meeting, ASH abstract 25-2587; NCT05254743) showed a favorable overall response rate (ORR) and a positive PFS trend with pirtobrutinib compared to the cBTKi ibrutinib in a subset of pts with treatment-naïve CLL. In BRUIN CLL-313, pirtobrutinib significantly improved IRC-assessed PFS versus BR for pts with treatment-naïve CLL/SLL with one of the largest treatment effects ever observed for a single-agent BTKi against this comparator. Pirtobrutinib was well tolerated, consistent with its known safety profile, with low rates of discontinuation and atrial fibrillation/flutter. While OS data remained immature, a notable trend favoring pirtobrutinib was observed, despite 52.9% of BR pts crossing over to receive pirtobrutinib after PD."

Clinical • Late-breaking abstract • P3 data • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • Small Lymphocytic Lymphoma • IGH

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma (ASH 2025) - P2 | "For instance, zanubrutinib, a newergeneration covalent BTK inhibitor (BTKi), showed an improved overall response rate (ORR) in combinationwith obinutuzumab compared to obinutuzumab alone (69% versus 46%) in the ROSEWOOD trial.Pirtobrutinib (pirto), a non-covalent BTKi, has also demonstrated an ORR of 50% in FL based on theBRUIN trial. If successful, itwill provide a more efficacious and safer treatment option in heavily treated FL. This approach (addingBTKi) may be applied more broadly in T cell-based immunotherapy in B cell lymphoma."

Clinical • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma (ASH 2025) - "Brexucel,lisocel, and the non-covalent BTKi pirto have been approved in this population...Ninety-one pts (86%) received chemo-immunotherapy (CIT), 16 (15%) autologous stem celltransplant, 19 (18%) venetoclax (ven), 29 (27%) chimeric antigen receptor T-cell, 4 (4%) allogeneic stemcell transplant. For cBTKi, 39 (35%) pts received ibrutinib, 56 (50%) pts acalabrutinib, 33 (30%) ptszanubrutinib, and 17 (15%) pts received more than one cBTKi... This is the first RW report on pirto in MCL pts. In this high-risk population, ORR to pirto wascomparable to the BRUIN trial, while PFS was significantly worse, especially in pts w/ no response to cBTKiand w/ a high Ki67. However, prolonged remissions were seen in a subset of pts, suggesting that a bettercharacterization of this population w/ durable benefit from pirto is needed."

Clinical • IO biomarker • Real-world • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • TP53

Docirbrutinib (AS-1763), a novel non-COVALENT BTK inhibitor, demonstrates efficacy in BTK inhibitor-resistant mutant cells (ASH 2025) - "Overexpression of the L528W mutant in OCI-Ly10 cells conferred resistance to both ibrutiniband pirtobrutinib; however, docirbrutinib retained its antiproliferative activity in these cells. Docirbrutinib is a novel ncBTKi characterized by a slow off-rate that enables sustained BTK inhibition,potentially leading to prolonged therapeutic effects similar to those of cBTKi. Profiling across a panel ofBTK mutants demonstrated that docirbrutinib is effective against both wild-type and multiple resistantBTK variants, including the kinase-dead L528W mutant. In combination with venetoclax, docirbrutinibinduced significant cell death in BTK-mutant OCI-Ly10 cells and primary CLL."

Clinical • IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (ASH 2025) - P1/2, P3 | "Pirtobrutinib, a noncovalent BTK inhibitor,was recently approved for patients who relapsed following covalent BTK inhibitor therapy such asibrutinib, acalabrutinib, or zanubrutinib. Secondary endpoints include overall survival, PFS by investigator (INV),overall response rate by IRC and INV, rate of partial response with lymphocytosis or higher by IRC andINV, duration of response by IRC and INV, time to next treatment, safety/tolerability per NCI CTCAE v5.0,and patient-reported outcomes. This study is actively recruiting."

Clinical • IO biomarker • P3 data • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Prolymphocytic Leukemia • Richter's Syndrome • Small Lymphocytic Lymphoma • BTK

The efficacy and safety of pirtobrutinib in patients with CLL/SLL: A phase 2 dose optimization trial in progress (ASH 2025) - P2 | "This study is a Trial in Progress."

Clinical • P2 data • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • Small Lymphocytic Lymphoma

Efficacy of pirtobrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A Bayesian network meta-analysis of randomized controlled trials (ASH 2025) - P3 | "Background BRUIN CLL-314 (NCT05254743) is a global phase 3 open-label randomized controlled trial (RCT)comparing pirtobrutinib with ibrutinib (ibr) in both treatment-naïve (TN) and relapsed/refractory patients(pts) with CLL/SLL and no prior BTKi exposure...Thisresulted in two disconnected networks of NCCN-recommended therapies: Network1 includedpirtobrutinib, ibr, and zanubrutinib (zanu); Network2 included venetoclax (ven) + obinutuzumab (obi), ven+ ibr, acala (acala), acala + obi, acala + ven, and acala + obi + ven.In Network1, pirtobrutinib had an 87.5% probability of being ranked first for ORR (surface under thecumulative ranking curve [SUCRA]=96.8%), followed by zanu (5.7% probability of being first,SUCRA=64.2%)...While the efficacy of pirtobrutinib as measured by ORR andpreliminary PFS generate favorable point estimates relative to currently available therapy (i.e., ORs > 1and HRs < 1), caution is needed when interpreting the data due to the wide..."

Monotherapy • Retrospective data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events (ASH 2025) - "Alternate covalent BTKi(acalabrutinib, zanubrutinib) and non-covalent BTKi (pirtobrutinib) have lower rates of CVAE in clinicaltrials compared with Ibr. BTKi are associated with increased risk of CVAE; 43% of pts on Ibr developed new onset HTNand 52% of pts discontinued Ibr due to a CVAE. Among pts with HTN on Ibr, transition to alternatecovalent BTKi was associated with a reduction in mean SBP as well as resolution of HTN, in somepatients, without an increase in number or dose of antihypertensive medications. Despite thedevelopment of HTN on Ibr, BP can improve after replacing Ibr with an alternate BTKi."

Adverse events • Clinical • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Hypertension

Pirtobrutinib versus usual care for patients with richter transformation of chronic lymphocytic leukemia: Inverse probability of treatment weighting-based analysis of BRUIN trial and mayo observational cohort (ASH 2025) - "The index line of RT treatment in the Mayo cohort included chemoimmunotherapy (n=167,80%) and novel agent-based therapy (eg, cBTKi, venetoclax, PI3Ki, immune checkpoint inhibitor, etc; n=42, 20%). This individual patient-level IPTW-based analysis demonstrated that single agentpirtobrutinib is associated with improved OS, PFS, and ORR compared to usual care in patients with RT.These results support the choice of pirtobrutinib over traditional therapies for RT. Although these resultsare encouraging, the durability of response to pirtobrutinib remains suboptimal. Ongoing trials and otherfuture research will evaluate the efficacy of pirtobrutinib in combination with other treatments in thissetting."

Clinical • Observational data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • TP53

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies (ASH 2025) - P1/2, P3 | " All 37 eligible patients (LOXO-BTK-18001, N=17; CLL-321, N=20) received pirtobrutinib 200 mgonce daily and received prior cBTKi treatment with ibrutinib (76%), acalabrutinib (14%), zanubrutinib (8%),or other cBTKi treatment (3%). Pirtobrutinib demonstrated clinical benefit and tolerability in patients with 2L CLL/SLLpreviously treated with a cBTKi, including those with high-risk genetic features. These findings supportthe potential use of pirtobrutinib as a 2L therapy option after 1L cBTKi use and may help inform futuretreatment sequencing strategies."

IO biomarker • Retrospective data • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Dental Disorders • Dermatology • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma • Stomatitis • IGH • TP53

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use (ASH 2025) - "In our real-world analysis, we found that pirtobrutinib utilizers were less likely to change therapycompared to non-pirtobrutinib utilizers. Since pirtobrutinib is a relatively new treatment, we were onlyable to examine a small number of utilizers with limited follow-up. As time progresses, we will re-analyzeour data to extend the follow-up period and increase the number of pirtobrutinib utilizers included in ouranalysis."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • BCL2

BTK regulates EZH2 stability in myeloid leukemia associated with down syndrome (ASH 2025) - "Although most ML-DS patients respond favorably to chemotherapy, outcomes remainpoor in relapsed or refractory cases, which highlights the need for novel therapeutic strategies.We previously demonstrated that dual inhibition of EZH2 and class I histone deacetylases (HDAC) byusing GSK126 and romidepsin synergistically suppressed ML-DS cell viability (Cicek et al., 2022)...Notably, BTK inhibition by Pirtobrutinib, a FDA-approved reversible BTK inhibitor,recapitulated the effects of combination treatment by reducing EZH2 protein level and inducing celldeath of relapsed ML-DS PDX cells via apoptosis. Proteosome inhibition with MG132 in the presence ofPirtobrutinib rescued EZH2 level, indicating that BTK inhibition reduces EZH2 stability via the ubiquitin-proteasome pathway. Furthermore, BTK inhibition suppressed key E2F-related oncogenic targets,including c-MYC, Bcl-xL and MCL-1, while upregulating the cell cycle inhibitor p21.Together, these findings highlight BTK as a novel..."

Acute Myelogenous Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Targeted Protein Degradation • ANXA5 • BCL2L1 • CASP3 • CASP7 • CD34 • GATA1 • MYC • RAD21 • STAG2 • SUZ12

Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators (ASH 2025) - "A total of64 blood samples were collected at different timepoints: baseline (before BTKi therapy), during treatmentand at disease progression from BTKi (Ibrutinib/Acalabrutinib/Pirtobrutinib/Nemtabrutinib). Disease progression of CLL on BTKi confirmed the existence of multiple driver genes beyondBTK, PLCG2 and TP53, including the high prevalence of mutations in MAPK pathway and epigeneticregulators, and increased genomic complexity. Ongoing efforts are focused on integrating these findingswith clinical demographics, epigenetic modifications, and preclinical drug sensitivity profiles."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Richter's Syndrome • BRAF • CREBBP • KMT2D • KRAS • NOTCH1 • NRAS • PLCG2 • PTPN11 • RB1 • SETD1A • SETD2 • SF3B1 • TP53

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia (ASH 2025) - "Real-world analysis of liso-cel for patients with relapsed/refractory CLL showed CR and ORR of 60.0% and83.3%, respectively. Despite having a heavily pre-treated and chemotherapy-exposed population andwith over half the patients having high-risk features, these response rates are higher than what wasdescribed in the TRANSCEND-CLL 004 clinical trial. These results are limited by the short follow-up periodand the variability in response assessment typical of a retrospective study."

Clinical • IO biomarker • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Inflammation • Leukemia • Rare Diseases • Richter's Syndrome • TP53

Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study (ASH 2025) - "Analysis of nemtabrutinib-treated cell lines using next-generation sequencing showed a lack of mutation in BTK and PLCγ2, incontrast with other covalent and noncovalent BTKi such as ibrutinib and pirtobrutinib, respectively (Qi etal, Blood Adv, 2023). These data show that across all biomarker-evaluable pts with R/R CLL/SLL receivingnemtabrutinib in BELLWAVE-003, acquired resistance mutations to BTKi were rare, regardless ofresponse. While BTK mutations are the most frequent mechanism of resistance to covalent BTKi andhave also been reported after treatment with non-covalent BTKi, none were detected in pts treated withnemtabrutinib. These data support the rationale for systematically evaluating the molecular basis ofacquired resistance, which may differ from mechanisms observed with other noncovalent BTKi."

IO biomarker • P2 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Small Lymphocytic Lymphoma • BCL2 • HEY1 • MYD88 • NOTCH1 • PLCG2 • SF3B1 • TP53

Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL) (ASH 2025) - "In vivo experiments using ibrutinib-resistant PDX MCL cells showed that pirtobrutinib treatment slowed disease progression and extendedsurvival by 1.5 and 2.5 weeks vs. ibrutinib or vehicle, respectively.Next, we conducted RNA-Seq analysis of sorted naïve T-cells from healthy donors treated withpirtobrutinib or ibrutinib for 24 hours. Pirtobrutinibalso facilitated immunologic synapse formation and enhanced T-cell cytotoxicity. These results providejustification for continued investigation of pirtobrutinib for treatment of lymphoid malignancies aloneand in combination with T-cell enabling therapies."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • CD40LG • CD69 • E2F2 • GZMB • ICAM1 • IFNG • IL2RA • IL4 • PD-1 • TNFA

Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma (ASH 2025) - "Background : Recent approvals and clinical trials have established covalent BTK inhibitors (BTKis),including ibrutinib, acalabrutinib, and zanubrutinib, as effective agents for the treatment of mantle celllymphoma...Additional approvals of the noncovalent BTKi pirtobrutinib andmultiple CAR T-cell therapies have also advanced the management of patients who have progressed oncovalent BTKi therapy... This analysis highlights the ongoing adoption of expert-recommended treatments into real-world clinical practice. Our data suggest that expert and HCP use of BTKi therapy in the ND MCL settinghas increased in recent years. In R/R MCL, CAR T-cell therapy appears to be considered infrequently byHCPs."

Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • TP53

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL) (ASH 2025) - P2 | "Bendamustine is the most commonly utilizedchemotherapy backbone in North America, however, it poses several challenges including risk ofinfections, risk for secondary malignancies and T-cell compromise affecting future cellular therapyoptions.Covalent BTK inhibitors (BTKis) have demonstrated efficacy in treating relapsed/refractory MZL withoverall response rates (ORR) ranging from 53 to 68%, but the long-term utility of covalent BTKis may belimited by toxicity and acquired BTK resistance. As of July 1, 2025, 6 patients have been enrolledwith a maximum expected sample size of 23 patients using Simon's two-stage minimax design (H0: ORR≤55% and Ha: ORR ≥80% with 80% power and one-sided type I error rate of 5%). Diagnostic tissue,peripheral blood and bone marrow aspirate from different timepoints are being banked with plannedexploratory analysis including minimal residual disease testing, targeted and whole exome sequencing,and transcriptomics."

Combination therapy • P2 data • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hepatitis C • Hepatology • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications (ASH 2025) - P2 | "Venetoclax and pirtobrutinib demonstrate comparable activity in relapsed or refractory WM,each with distinct limitations. TP53 and CXCR4 mutations predicted inferior outcomes to venetoclax andpirtobrutinib, respectively, suggesting non-overlapping molecular vulnerabilities. Venetoclax post-cBTKiwas limited by reduced efficacy and IgM rebound."

Clinical • Hematological Disorders • Lymphoma • Lymphoplasmacytic Lymphoma • Waldenstrom Macroglobulinemia • CXCR4

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study (ASH 2025) - P2 | "Nemtabrutinib has additional activity versus ibrutinib against Srcfamily kinases and kinases related to ERK signaling, which may produce robust responses...Furthermore, nemtabrutinib has also showed preclinical efficacy in cell linescarrying BTK mutations derived from patients treated with pirtobrutinib... With additional follow-up, nemtabrutinib continued to show promising antitumor efficacy inparticipants with FL who had received multiple prior lines of therapy and had progressed on bothchemoimmunotherapy and immunomodulatory therapy. The safety profile remained manageable, withno unexpected AEs observed. These results support the ongoing clinical evaluation of nemtabrutinib inthe R/R setting for FL."

Clinical • IO biomarker • P2 data • Cardiovascular • Chronic Lymphocytic Leukemia • CNS Disorders • Congestive Heart Failure • Dermatology • Follicular Lymphoma • Heart Failure • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Neutropenia • Pneumonia • Respiratory Diseases • Richter's Syndrome • Septic Shock • Thrombocytopenia • Urticaria • Waldenstrom Macroglobulinemia